How do these ten research topics differ?
The studies and labels in this comparison address different outcomes: compound identity, short-term hormone or appetite changes, postoperative recovery, and specified medicine indications. This is a comparison of those findings, not a list of the most effective or safest products. MK-677 is included as a related oral ghrelin-mimetic topic. FDA BPC-157 assessment (2026), GHRP-2 appetite and hormone study, Ipamorelin postoperative trial, WEGOVY prescribing information, MK-677 randomized older-adult study.
BPC-157: identity and compounding safety concerns
FDA's July 2026 briefing describes BPC-157 as a 15-amino-acid fragment of BPC. Its compounding safety communication identifies potential immune-response risks, peptide impurities and difficulty characterizing the active ingredient in compounded BPC-157. Those concerns are not evidence of injury-healing efficacy or a test result for a particular vial. The BPC-157 guide covers the fuller human and preclinical evidence discussion. FDA BPC-157 assessment (2026), FDA compounded-substance safety concerns.
CJC-1295: with DAC and without DAC are different evidence questions
FDA's December 2024 briefing describes CJC-1295 without DAC as a synthetic 29-amino-acid growth hormone-releasing-hormone analogue. It explicitly states that CJC-1295 DAC pharmacology cannot be extrapolated to the substance without DAC. The modification therefore changes which research describes the named compound. See the CJC-1295 guide for that distinction. FDA CJC-1295 assessment (2024).
Ipamorelin: the postoperative trial did not show efficacy differences
The 2014 ipamorelin phase 2 study was a multicentre, double-blind, placebo-controlled trial in adults undergoing bowel resection. It found no significant differences from placebo in its key or secondary efficacy analyses. These results concern postoperative ileus, rather than muscle gain or recovery in healthy users. Ipamorelin postoperative trial.
FDA separately distinguishes intravenous gastric-motility research from other injectable routes for which it had not identified safety information. The ipamorelin guide keeps those research and route limits separate. FDA compounded-substance safety concerns.
MK-677: more fat-free mass did not mean better function
A 2008 randomized, placebo-controlled study of the oral ghrelin mimetic MK-677 enrolled 65 healthy adults aged 60 to 81. Fat-free mass increased without an observed improvement in strength or function. Fasting glucose increased and insulin sensitivity decreased. Those combined results do not support a simple muscle-performance or youth-preservation promise. Read the separate MK-677 guide. MK-677 randomized older-adult study.
TB-500: the exact fragment matters
FDA's July 2026 evaluation identifies TB-500 as a synthetic seven-amino-acid fragment of thymosin beta-4. The briefing says that the pharmacological profile of non-acetylated LKKTETQ cannot be directly transferred to N-acetylated TB-500. Full protein and fragment names cannot be treated as interchangeable evidence. The TB-500 guide explains the substance distinction. FDA TB-500 assessment (2026).
GHRP-6: specific overnight hormone and sleep findings
The cited GHRP-6 study compared repetitive intravenous exposure with placebo in normal male controls, measuring overnight sleep EEG and growth hormone, ACTH and cortisol profiles. Stage 2 sleep increased, slow-wave sleep was unchanged, and GH, ACTH and cortisol secretion increased. These are acute study findings, rather than an overall sleep-quality or long-term body-composition result. See GHRP-6. GHRP-6 sleep and hormone study.
GHRP-2: acute appetite and hormone effects
A double-blind, randomized GHRP-2 study tested 19 healthy, weight-stable adults: 10 lean and nine obese participants. During short subcutaneous infusions across three study visits, food intake and growth hormone increased. The experiment measured acute intake and hormone responses, not long-term muscle or fat outcomes. The GHRP-2 guide discusses that research context. GHRP-2 appetite and hormone study.
Semaglutide: a named weight-management medicine indication
Semaglutide acts as a GLP-1 receptor agonist. In the United States, the WEGOVY injection weight-reduction indication covers adults and pediatric patients aged 12 years or older with obesity, or adults with overweight and at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity. WEGOVY prescribing information.
In WEGOVY's placebo-controlled adult weight-reduction trials, nausea, diarrhea, vomiting, constipation and abdominal pain were among reactions reported in at least 2% of treated participants and more often than with placebo. WEGOVY is contraindicated with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. The semaglutide guide covers the named product label. WEGOVY prescribing information.
Tirzepatide: GIP/GLP-1 activity and ZEPBOUND's indications
Tirzepatide acts at GIP and GLP-1 receptors. The US ZEPBOUND label indicates long-term weight reduction for adults with obesity, or adults with overweight and at least one weight-related comorbid condition, with a reduced-calorie diet and increased physical activity. It also indicates treatment of moderate to severe obstructive sleep apnea in adults with obesity under those diet-and-activity conditions. ZEPBOUND prescribing information.
ZEPBOUND's adult weight-management trials listed nausea, diarrhea, vomiting, constipation and abdominal pain among reactions reported in at least 2% of treated participants and more frequently than with placebo. Its label contraindicates the medicine with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. See the tirzepatide guide. ZEPBOUND prescribing information.
Sermorelin: identity and a historical pediatric growth study
NLM MeSH defines sermorelin as the biologically active human growth-hormone-releasing-factor fragment GHRH(1-29)-amide; PubChem lists GHRH(1-29)NH2 among its synonyms. This connects the peptide name to the material named in the historical study, without establishing a supplier's salt form or formulation. NLM sermorelin definition, PubChem sermorelin synonyms.
A six-month randomized study compared GHRH(1-29)-NH2 with growth hormone in 43 prepubertal children with growth hormone deficiency of hypothalamic origin. Height velocity was lower in the lower-exposure GHRH group and comparable in the higher-exposure GHRH and GH groups. This is a pediatric deficiency result, not an adult wellness or anti-aging finding. Read sermorelin for the separate guide. GHRH(1-29)-NH2 pediatric growth study.
What can be compared across the ten topics?
A rise in a hormone, a change in body composition and a clinical improvement are different outcomes. MK-677's older-adult trial illustrates the distinction: fat-free mass increased without better strength or function. The ipamorelin trial found no significant efficacy differences in its postoperative population, while the named WEGOVY and ZEPBOUND labels have specified patient indications. None of those observations authenticates a supplier product or supplies Thai registration. MK-677 randomized older-adult study, Ipamorelin postoperative trial, WEGOVY prescribing information, ZEPBOUND prescribing information.
